Aslan Pharmaceuticals Ltd
NASDAQ:ASLN
Relative Value
The Relative Value of one ASLN stock under the Base Case scenario is 4.308 USD. Compared to the current market price of 0.4244 USD, Aslan Pharmaceuticals Ltd is Undervalued by 90%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
ASLN Competitors Multiples
Aslan Pharmaceuticals Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
SG |
Aslan Pharmaceuticals Ltd
NASDAQ:ASLN
|
9.6m USD | 0.8 | -0.8 | 0.5 | 0.5 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.4B USD | 5.3 | 59.6 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
160.6B USD | 5.4 | 42.7 | 18.2 | 29.9 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.6B USD | 8.1 | 27.4 | 22.1 | 24.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.7B USD | 10.5 | 28.7 | 22.9 | 24 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 168.7 | 6.8 | 8.9 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.8B USD | 9.1 | -7.8 | -8.5 | -7.6 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.2B USD | 3.3 | 27.6 | 14.1 | 17.7 | ||
KR |
Celltrion Inc
KRX:068270
|
40.2T KRW | 18.5 | 75.1 | 45.9 | 63.2 |